Elicio Therapeutics Reports Inducement Grants
Elicio Therapeutics (Nasdaq: ELTX), a clinical-stage biotech company focused on cancer immunotherapies, has announced the granting of 4,800 inducement stock options to a new employee. This grant, approved by the Compensation Committee of Elicio's Board of Directors, was made under the company's 2024 Inducement Incentive Award Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options allow for the purchase of Elicio common stock at $4.13 per share, which was the closing price on September 16, 2024, the date of grant. The options have a four-year vesting schedule, with 25% vesting on the first anniversary of the employee's start date and the remainder vesting monthly thereafter, contingent on continued employment with Elicio.
Elicio Therapeutics (Nasdaq: ELTX), una società biotecnologica in fase clinica focalizzata sulle immunoterapie contro il cancro, ha annunciato l'assegnazione di 4.800 opzioni su azioni incentivanti a un nuovo dipendente. Questa concessione, approvata dal Comitato per la Compensazione del Consiglio di Amministrazione di Elicio, è stata effettuata nell'ambito del Piano di Assegnazione Incentivante per il 2024 della società, in conformità con la Regola di Quotazione Nasdaq 5635(c)(4).
Le opzioni su azioni permettono l'acquisto di azioni ordinarie di Elicio a $4.13 per azione, che era il prezzo di chiusura del 16 settembre 2024, data della concessione. Le opzioni hanno un programma di maturazione di quattro anni, con il 25% che matura al primo anniversario della data di assunzione del dipendente e il resto matura mensilmente successivamente, a condizione di un impiego continuativo con Elicio.
Elicio Therapeutics (Nasdaq: ELTX), una empresa biotecnológica en etapa clínica centrada en inmunoterapias contra el cáncer, ha anunciado la concesión de 4,800 opciones sobre acciones de incentivo a un nuevo empleado. Esta concesión, aprobada por el Comité de Compensación de la Junta Directiva de Elicio, se realizó bajo el Plan de Asignación de Incentivo 2024 de la compañía de acuerdo con la Regla de Cotización Nasdaq 5635(c)(4).
Las opciones sobre acciones permiten la compra de acciones ordinarias de Elicio a $4.13 por acción, que fue el precio de cierre del 16 de septiembre de 2024, fecha de la concesión. Las opciones tienen un cronograma de adquisición de cuatro años, con un 25% adquirido en el primer aniversario de la fecha de inicio del empleado y el resto adquiriéndose mensualmente a partir de entonces, condicionadas a la continuidad en el empleo con Elicio.
엘리시오 테라퓨틱스(Elicio Therapeutics) (Nasdaq: ELTX)는 암 면역 요법에 중점을 둔 임상 단계의 생명공학 회사로, 새로운 직원에게 4,800개의 유도 주식 옵션을 부여했다고 발표했습니다. 이 부여는 엘리시오 이사회 보상의 위원회에서 승인되었으며, 회사의 2024 유도 인센티브 수여 계획에 따라 나스닥 상장 규칙 5635(c)(4)에 부합하여 이루어졌습니다.
주식 옵션은 2024년 9월 16일, 부여일의 종가인 $4.13 per share에 엘리시오 보통주를 구매할 수 있도록 허용합니다. 옵션은 4년의 만기 일정을 가지고 있으며, 직원의 근무 시작일 1주년 기념일에 25%가 만기되고, 이후에는 매달 나머지가 만기되며, 엘리시오에 계속 재직하는 조건이 붙습니다.
Elicio Therapeutics (Nasdaq: ELTX), une entreprise biopharmaceutique en phase clinique spécialisée dans les immunothérapies contre le cancer, a annoncé l'octroi de 4 800 options d'actions d'incitation à un nouvel employé. Cet octroi, approuvé par le Comité de Rémunération du Conseil d'Administration d'Elicio, a été effectué dans le cadre du Plan d'Attribution d'Incitation 2024 de la société conformément à la Règle de Cotation Nasdaq 5635(c)(4).
Les options d'actions permettent l'achat d'actions ordinaires d'Elicio au prix de $4,13 par action, qui était le prix de clôture du 16 septembre 2024, date d'octroi. Les options ont un calendrier d'acquisition de quatre ans, avec 25 % qui s'acquiert au premier anniversaire de la date de début de l'employé et le reste s'acquiert mensuellement par la suite, sous réserve d'un emploi continu auprès d'Elicio.
Elicio Therapeutics (Nasdaq: ELTX), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Krebsimmuntherapien konzentriert, hat die Gewährung von 4.800 Anreizaktienoptionen an einen neuen Mitarbeiter bekannt gegeben. Diese Gewährung wurde vom Vergütungsausschuss des Vorstands von Elicio genehmigt und erfolgte im Rahmen des Anreizvergabeplans 2024 der Gesellschaft gemäß der Nasdaq-Listing-Regel 5635(c)(4).
Die Aktienoptionen ermöglichen den Kauf von Elicio-Stammaktien zu $4,13 pro Aktie, dem Schlusskurs vom 16. September 2024, dem Datum der Gewährung. Die Optionen haben einen Vesting-Zeitraum von vier Jahren, wobei 25 % am ersten Jahrestag des Beschäftigungsbeginns des Mitarbeiters fällig werden und der Rest anschließend monatlich fällig wird, vorbehaltlich des Fortbestehens des Arbeitsverhältnisses mit Elicio.
- Elicio Therapeutics is attracting new talent, potentially strengthening its workforce
- The company has a structured employee incentive program in place, which may help with retention and motivation
- The stock option grant may lead to potential dilution for existing shareholders
BOSTON, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on September 16, 2024, Elicio granted an aggregate of 4,800 inducement stock options to a new employee, as an inducement material to the individual entering into employment with Elicio in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement stock options were approved by the Compensation Committee of Elicio’s Board of Directors and granted under the Elicio Therapeutics, Inc. 2024 Inducement Incentive Award Plan.
The grant provides for the purchase of shares of Elicio common stock at a price of
The grant vests over four years, with 25 percent of the shares vesting on the first anniversary of the employee’s start date, and the remainder vesting ratably at the end of each subsequent month thereafter, subject to such employee’s continued service relationship with Elicio through the applicable vesting dates.
About Elicio Therapeutics
Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company advancing a pipeline of novel lymph node-targeted immunotherapies for the treatment of some of the most aggressive cancers. By combining expertise in immunology and immunotherapy, Elicio is harnessing the natural power of the immune system with the AMP technology, which allows for therapeutic payloads to be delivered directly to the lymph nodes, with the goal of enhancing the immune system’s cancer-fighting capabilities. By targeting cancer immunotherapies to the core of the immune response, AMP aims to optimize the lymph nodes’ natural ability to educate, activate and amplify cancer-specific T cells, which are essential for recognizing and eliminating tumor cells. Engineered to synchronize immunity in these highly potent sites, AMP is built to enhance the magnitude, potency, quality and durability of the immune response to drive antitumor activity. Elicio’s R&D pipeline includes off-the-shelf therapeutic cancer vaccines ELI-002, (targeting mKRAS-driven cancers) as well as ELI-007 and ELI-008 (targeting BRAF-driven cancers and p53 hotspot mutations, respectively). For more information, please visit www.elicio.com.
Investor Relations Contact
Robert Connelly
Elicio Therapeutics
IR@elicio.com
857-209-0153
FAQ
How many inducement stock options did Elicio Therapeutics (ELTX) grant on September 16, 2024?
What is the strike price for the inducement stock options granted by Elicio Therapeutics (ELTX)?
What is the vesting schedule for the inducement stock options granted by Elicio Therapeutics (ELTX)?
Under which plan were the inducement stock options granted by Elicio Therapeutics (ELTX)?
